Oncology · Cervical CancerTrial Updateclinicalmid-term

IAP Overexpression May Predict Recurrence in Locally Advanced Cervical Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 6:34:03 PM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The investigation into IAP overexpression as a prognostic marker in cervical cancer could significantly influence treatment decisions and patient management strategies. If validated, this biomarker may lead to the development of targeted therapies, enhancing clinical outcomes and positioning in the oncology market. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 26 ranked evidence items (10 high-relevance).

Strategic Assessment

The strongest clinical anchor is Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer (ClinicalTrials.gov), entity match (institut du cancer de montpellier - val d aurelle); patient population match (advanced). In Oncology · Cervical Cancer, 6 regulatory and 4 competitive items passed relevance filtering for Institut du Cancer de Montpellier - Val d'Aurelle. Successful identification of IAP overexpression as a prognostic marker could open new avenues for IAP-targeted therapies, potentially increasing market share in the cervical cancer segment.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer); patient population match (advanced). Secondary pressure from NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers. If IAP overexpression is confirmed as a prognostic marker, it could influence treatment decisions and patient management strategies in cervical cancer.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). If IAP overexpression is confirmed as a significant prognostic factor, it may necessitate updates to treatment guidelines and could influence regulatory submissions for new therapies or diagnostics.

Key Risks

Elevated medium regulatory exposure for Institut du Cancer de Montpellier - Val d'Aurelle could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Institut du Cancer de Montpellier - Val d'Aurelle through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Successful identification of IAP overexpression as a prognostic marker could open new avenues for IAP-targeted therapies, potentially increasing market share in the cervical cancer segment.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Institut du Cancer de Montpellier - Val d'Aurelle may improve if A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor results from this trial for insights on IAP overexpression's impact on recurrence rates and potential clinical applications.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAhigh relevance
Patient population match (advanced)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
ClinicalTrials.govhigh relevance
Entity match (institut du cancer de montpellier - val d aurelle); Patient population match (advanced)
FDA document
View source
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Trea
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
Humanexa Signalshigh relevance
Patient population match (advanced)
Phase Ⅲ Trial of Rilvegostomig in HER2-positive Gastric Cancer Initiated by AstraZeneca
Humanexa Signalsmedium relevance
Sponsor/company relevance (AstraZeneca)
Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
TGFA promotes the development of cervical cancer via interacting with DSG2.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cervical cancer and screening: Knowledge, attitudes, and adherence among university students in Italy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Institut du Cancer de Montpellier - Val d'Aurelle
cervical cancer treatment protocols

Commercial impact

medium

Successful identification of IAP overexpression as a prognostic marker could open new avenues for IAP-targeted therapies, potentially increasing market share in the cervical cancer segment.

Regulatory impact

medium

If IAP overexpression is confirmed as a significant prognostic factor, it may necessitate updates to treatment guidelines and could influence regulatory submissions for new therapies or diagnostics.

What to watch

Monitor results from this trial for insights on IAP overexpression's impact on recurrence rates and potential clinical applications.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.